title: 1 alpha(OH)D3 treatment and procollagen III (PC III) studies in idiopathic myelofibrosis.
abstract: Eight patients with idiopathic myelofibrosis (IMF) were treated with escalating doses (0.5 microgram/day to 4.0 micrograms/day) of 1 alpha(OH)D3 for periods up to 6 months. The treatment did not improve the disease parameters in any of the patients under study. No patient demonstrated a decrease in bone marrow fibrosis as determined by serial procollagen (PC III) serum level analysis. Although 1 alpha(OH)D3 was well tolerated at the administered doses, the therapeutic value of this treatment for IMF requires further evaluation.
authors.forename: C
authors.initials: C
authors.lastname: Tsatalas
authors.forename: G
authors.initials: G
authors.lastname: Curtoglou
authors.forename: D
authors.initials: D
authors.lastname: Fotopoulos
authors.forename: P
authors.initials: P
authors.lastname: Halkia
authors.forename: A T
authors.initials: AT
authors.lastname: Vyzantiadis
authors.forename: Z
authors.initials: Z
authors.lastname: Sinakos
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood*; D055728:Primary Myelofibrosis / Q000097:blood / Q000188:drug therapy*; D011347:Procollagen / Q000097:blood*
chemical_list: D006887:Hydroxycholecalciferols; D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; C008088:alfacalcidol